In this talk, Catenion senior partner Christian Elze turns the buzzword “bioconvergence” into something biopharma executives can use for strategy. His main argument is that technology alone does not explain it: the dynamics of the ecosystem in which innovation takes place matter just as much.
- Definition and history: starting from the MIT reports on convergence (2011 and 2016), he traces the application of physical sciences to biology back about 125 years. He contrasts a broad version of bioconvergence, in which almost everything becomes intertwined with biology (for example synthetic biology), with the more prevalent and less revolutionary view that new tools such as machine learning, CRISPR and single-cell sequencing will make biopharma R&D more efficient. He doubts there will be enough primary data to unravel the complexity of biological systems, and stresses that better tools are not the same as a better understanding of what to manipulate.
- Innovation S-curves: biopharma innovation moved through a first S-curve of symptomatic, mostly small-molecule treatments (1930s to 1970s) and a second of precision, target-driven medicine, starting with hybridoma and recombinant DNA technology. An emerging curve points to curative treatments for ever smaller populations and many new modalities, which he describes as the bioconvergence innovation system.
- Emerging platforms: cell and gene therapies, oligonucleotides and RNA vaccines, digital health, regenerative medicine (including bioprinting of organoids), bioelectronics, brain-machine interfaces, optogenetics and biomaterials. Many of these sit closer to surgery and medical devices than to drugs, so development, approval, pricing and reimbursement may follow different rules.
- The innovation ecosystem: since the 1980s, innovation has been financed by venture capital and big pharma profits, practiced by VC-funded startups and focused big pharma, and underpinned by NIH funding and rising net prices. He argues that this model under-leverages the potential of science and appears financially unsustainable: biotechs are built for financial exit, good academic ideas never reach the clinic, and incentives favor oncology and rare diseases over large-burden areas.
- Possible futures: players from other industries (medtech, healthcare providers, big tech, multi-technology conglomerates) may become co-innovators, price levels may converge downwards, and public grant-based funding agencies (inspired by DARPA and by bodies such as the California Institute for Regenerative Medicine) could reduce the role of expensive risk capital in the early stages.
- Implications for strategy: companies will need engineering-style project management skills, strong links to early-stage academic research beyond biology, and a culture and language that bridge reductionist engineering and the complexity of biology. Strategy should consider scenarios of ecosystem change instead of taking the current ecosystem for granted.



